Clinical protocols for the isolation and expansion of mesenchymal stromal cells

Transfusion Medicine and Hemotherapy

Volumn 35, Issue 4, 2008, Pages 286-294

  Bieback, Karen ^a   Schallmoser, Katharina ^b   Klüter, Harald ^a   Strunk, Dirk ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Clinical scale expansion; Good Manufacturing Practice (GMP); Mesenchymal stromal cells, multipotent

Indexed keywords

ENDOTOXIN; PYROGEN;

ADIPOSE TISSUE; BIOREACTOR; BONE MARROW; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL VIABILITY; CLINICAL PROTOCOL; CLONOGENESIS; CULTURE MEDIUM; DEVICE; HEMATOPOIESIS; HUMAN; IMMUNOPHENOTYPING; MESENCHYME CELL; MICROBIOLOGICAL EXAMINATION; QUALITY CONTROL; REVIEW; SAFETY; STROMA CELL;

EID: 58549115920     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141567     Document Type: Review

References (92)

1. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995;16:557-564.
2. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-8937.
3. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA: A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48:1416-1423.
4. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
5. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-1301.
6. Bieback K, Kern S, Kocaomer A, Ferlik K, Bugert P: Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng 2008;18(suppl 1):S71-76.
7. Bartmann C, Rohde E, Schallmoser K, Purstner P, Lanzer G, Linkesch W, Strunk D: Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007;47:1426-1435.
8. Reinisch A, Bartmann C, Rohde E, Schallmoser K, Bjelic-Radisic V, Lanzer G, Linkesch W, Strunk D: Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med 2007;2:371-382.
9. Rojewski M, Weber B, Schrezenmeier H: Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemother 2008;35:168-184.
10. Bieback K: Basic biology of mesenchymal stem cells. Transfus Med Hemother 2008;35:151-152.
11. Schaefer R, Northoff H: Characteristics of mesenchymal stem cells - new stars in regenerative medicine or unrecognized old fellows in autologous regeneration? Transfus Med Hemother 2008;35:154-159.
12. Bifari F, Lisi V, Mimiola E, Pasini A, Krampera M: Immune modulation by mesenchymal stem cells. Transfus Med Hemother 2008;35:194-204.
13. Gimble JM, Guilak F, Nuttall ME, Sathishkumar S, Vidal M, Bunnell BA: In vitro differentiation potential of mesenchymal stem cells. Transfus Med Hemother 2008;35:228-238.
14. Caplan AI: Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341-347.
15. Subbanna PK: Mesenchymal stem cells for treating GVHD: in-vivo fate and optimal dose. Med Hypotheses 2007;69:469-470.
16. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A: Co-transplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11:389-398.
17. Bain BJ: Bone marrow aspiration. J Clin Pathol 2001;54:657-663.
18. Stolzing A, Jones E, McGonagle D, Scutt A: Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008;129:163-173.
19. Muschler GF, Boehm C, Easley K: Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am 1997;79:1699-1709.
20. Abdallah BM, Kassem M: Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther 2008;15:109-116.
21. Guo KT, Schaefer R, Paul A, Gerber A, Ziemer G, Wendel HP: A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 2006;24:2220-2231.
22. Gentry T, Foster S, Winstead L, Deibert E, Fiordalisi M, Balber A: Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy 2007;9:259-274.
23. Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M: Isolation and characterization of CD146(+) multipotent mesenchymal stromal cells. Exp Hematol 2008(Epub ahead of print).
24. Fluks AJ: Three-step isolation of human blood monocytes using discontinuous density gradients of Percoll. J Immunol Methods 1981;41:225-233.
25. Lange C, Schroeder J, Stute N, Lioznov MV, Zander AR: High-potential human mesenchymal stem cells. Stem Cells Dev 2005;14:70-80.
26. Aktas M, Radke TF, Strauer BE, Wernet P, Kogler G: Separation of adult bone marrow mononuclear cells using the automated closed separation system Sepax. Cytotherapy 2008;10:203-211.
27. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
28. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ: Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002;20:530-541.
29. Schallmoser K, Rohde E, Reinisch A, Bartmann C, Thaler D, Drexler C, Obenauf AC, Lanzer G, Linkesch W, Strunk D: Rapid large scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng 2008(in press).
30. Schaffler A, Buchler C: Concise review: adipose tissue-derived stromal cells - basic and clinical implications for novel cell-based therapies. Stem Cells 2007;25:818-827.
31. Moseley TA, Zhu M, Hedrick MH: Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg 2006;118(suppl 3):121S-128S.
32. Gimble JM, Katz AJ, Bunnell BA: Adipose-derived stem cells for regenerative medicine. Circ Res 2007;100:1249-1260.
33. Oedayrajsingh-Varma MJ, van Ham SM, Knippenberg M, Helder MN, Klein-Nulend J, Schouten TE, Ritt MJ, van Milligen FJ: Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy 2006;8:166-177.
34. Dubois SG, Floyd EZ, Zvonic S, Kilroy G, Wu X, Carling S, Halvorsen YD, Ravussin E, Gimble JM: Isolation of human adipose-derived stem cells from biopsies and liposuction specimens. Methods Mol Biol 2008;449:69-79.
35. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH: Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211-228.
36. Katz AJ, Hedrick MH, Llull R, Futrell JW: A novel device for the simple and efficient refinement of liposuctioned tissue. Plast Reconstr Surg 2001;107:595-597.
37. Duckers HJ, Pinkernell K, Milstein AM, Hedrick MH: The Bedside Celution™ system for isolation of adipose derived regenerative cells. EuroIntervention 2006;2:395-398.
38. DiMuzio P, Tulenko T: Tissue engineering applications to vascular bypass graft development: the use of adipose-derived stem cells. J Vasc Surg 2007;45(suppl A):A99-103.
39. Both SK, van der Muijsenberg AJ, van Blitterswijk CA, de Boer J, de Bruijn JD: A rapid and efficient method for expansion of human mesenchymal stem cells. Tissue Eng 2007;13:3-9.
40. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M: Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006;24:462-471.
41. Bieback K, Kern S, Kluter H, Eichler H: Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004;22:625-634.
42. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP: Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997;64:295-312.
43. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
44. Caterson EJ, Nesti LJ, Danielson KG, Tuan RS: Human marrow-derived mesenchymal progenitor cells: isolation, culture expansion, and analysis of differentiation. Mol Biotechnol 2002;20:245-256.
45. Asher DM: Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies. Dev Biol Stand 1999;99:41-44.
46. Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products. EMEA CPMP/BWP/1793/02;2003.
47. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. EMEA/410/01 rev2;2004.
48. Martin MJ, Muotri A, Gage F, Varki A: Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005;11:228-232.
49. Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola M, Olsson C, Miller-Podraza H, Blomqvist M, Olonen A, Salo H, Lehenkari P, Tuuri T, Otonkoski T, Natunen J, Saarinen J, Laine J: N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007;25:197-202.
50. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ: Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004;9:747-756.
51. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K: No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007;92:1208-1215.
52. Mannello F, Tonti GA: Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells 2007;25:1603-1609.
53. Gruber R, Varga F, Fischer MB, Watzek G: Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res 2002;13:529-535.
54. Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M: The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 2006;17:212-219.
55. Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AM, Meotti C, Bertoja AZ, Giardino R, Fornasari PM, Mercuri M, Picci P: Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials 2003;24:3095-3100.
56. Kilian O, Flesch I, Wenisch S, Taborski B, Jork A, Schnettler R, Jonuleit T: Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. Eur J Med Res 2004;9:337-344.
57. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR: Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638-646.
58. Lucarelli E, Fini M, Beccheroni A, Giavaresi G, Di Bella C, Aldini NN, Guzzardella G, Martini L, Cenacchi A, Di Maggio N, Sangiorgi L, Fornasari PM, Mercuri M, Giardino R, Donati D: Stromal stem cells and platelet-rich plasma improve bone allograft integration. Clin Orthop Relat Res 2005;435:62-68.
59. Kocaoemer A, Kern S, Kluter H, Bieback K: Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007;25:1270-1278.
60. Yamaguchi M, Hirayama F, Wakamoto S, Fujihara M, Murahashi H, Sato N, Ikebuchi K, Sawada K, Koike T, Kuwabara M, Azuma H, Ikeda H: Bone marrow stromal cells prepared using AB serum and bFGF for hematopoietic stem cells expansion. Transfusion 2002;42:921-927.
61. Anselme K, Broux O, Noel B, Bouxin B, Bascoulergue G, Dudermel AF, Bianchi F, Jeanfils J, Hardouin P: In vitro control of human bone marrow stromal cells for bone tissue engineering. Tissue Eng 2002;8:941-953.
62. Le Blanc K, Samuelsson H, Lonnies L, Sundin M, Ringden O: Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation 2007;84:1055-1059.
63. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE: In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005;23:1357-1366.
64. Gregory CA, Reyes E, Whitney MJ, Spees JL: Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogenic species-specific serum and administration in fibrin constructs. Stem Cells 2006;24:2232-2243.
65. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M: Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005;308:1472-1477.
66. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V: PDGF, TGF-b and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSC into adipogenic, chondrogenic and osteogenic lineages. Blood 2008(Epub ahead of print).
67. Tsutsumi S, Shimazu A, Miyazaki K, Pan H, Koike C, Yoshida E, Takagishi K, Kato Y: Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun 2001;288:413-419.
68. Kogler G, Sensken S, Wernet P: Comparative generation and characterization of pluripotent unrestricted somatic stem cells with mesenchymal stem cells from human cord blood. Exp Hematol 2006;34:1589-1595.
69. De Boer J, Wang HJ, Van Blitterswijk C: Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng 2004;10:393-401.
70. Ebert R, Ulmer M, Zeck S, Meissner-Weigl J, Schneider D, Stopper H, Schupp N, Kassem M, Jakob F: Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. Stem Cells 2006;24:1226-1235.
71. Stolzing A, Coleman N, Scutt A: Glucose-induced replicative senescence in mesenchymal stem cells. Rejuvenation Res 2006;9:31-35.
72. Li YM, Schilling T, Benisch P, Zeck S, Meissner-Weigl J, Schneider D, Limbert C, Seufert J, Kassem M, Schutze N, Jakob F, Ebert R: Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem Biophys Res Commun 2007;363:209-215.
73. Sensebe L: Clinical grade production of mesenchymal stem cells. Biomed Mater Eng 2008;18(suppl 1):S3-10.
74. Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D: Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007;47:1436-1446.
75. Gastens MH, Goltry K, Prohaska W, Tschope D, Stratmann B, Lammers D, Kirana S, Gotting C, Kleesiek K: Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Cell Transplant 2007;16:685-696.
76. Dennis JE, Esterly K, Awadallah A, Parrish CR, Poynter GM, Goltry KL: Clinical-scale expansion of a mixed population of bone-marrow-derived stem and progenitor cells for potential use in bone-tissue regeneration. Stem Cells 2007;25:2575-2582.
77. Baksh D, Zandstra PW, Davies JE: A non-contact suspension culture approach to the culture of osteogenic cells derived from a CD49elow subpopulation of human bone marrow-derived cells. Biotechnol Bioeng 2007;98:1195-1208.
78. Baksh D, Davies JE, Zandstra PW: Adult human bone marrow-derived mesenchymal progenitor cells are capable of adhesion-independent survival and expansion. Exp Hematol 2003;31:723-732.
79. Chen X, Xu H, Wan C, McCaigue M, Li G: Bioreactor expansion of human adult bone marrow-derived mesenchymal stem cells. Stem Cells 2006;24:2052-2059.
80. Xie Y, Hardouin P, Zhu Z, Tang T, Dai K, Lu J: Three-dimensional flow perfusion culture system for stem cell proliferation inside the critical-size beta-tricalcium phosphate scaffold. Tissue Eng 2006;12:3535-3543.
81. Zhao F, Pathi P, Grayson W, Xing Q, Locke BR, Ma T: Effects of oxygen transport on 3-d human mesenchymal stem cell metabolic activity in perfusion and static cultures: experiments and mathematical model. Biotechnol Prog 2005;21:1269-1280.
82. Rohde E, Schallmoser K, Bartmann C, Reinisch A, Strunk D: GMP-compliant propagation of human multipotent mesenchymal stromal cells; in Gad SC (ed): Pharmaceutical Manufacturing Handbook: Regulations and Quality. Hoboken, NJ, John Wiley and Sons, 2008, pp 97-115.
83. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
84. Bruchmuller I, Pirkl E, Herrmann R, Stoermer M, Eichler H, Kluter H, Bugert P: Introduction of a validation concept for a PCR-based Mycoplasma detection assay. Cytotherapy 2006;8:62-69.
85. Guideline on validation of the Limulus amebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices. 1987, sections I-IV: http://www.fda.gov/cber/ gdlns/lal.pdf.
86. Luria EA, Panasyuk AF, Friedenstein AY: Fibroblast colony formation from monolayer cultures of blood cells. Transfusion 1971;11:345-349.
87. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA: Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83-92.
88. Pittenger MF, Martin BJ: Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20.
89. Delorme B, Chateauvieux S, Charbord P: The concept of mesenchymal stem cells. Regen Med 2006;1:497-509.
90. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
91. Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, Kaur I, Fu P, Del Angel M, Messinger R, Flagge F, de Lima M, Decker W, Xing D, Champlin R, Shpall EJ: Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 2006;37:359-366.
92. Zhang Y, Chai C, Jiang XS, Teoh SH, Leong KW: Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells. Tissue Eng 2006;12:2161-2170.